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Summary Atopic dermatitis (AD) is a common problem of childhood causing considerable
distress. Effective topical treatments exist, yet poor adherence often results in poor
outcomes. A framework is needed to better understand adherence behaviour. To
provide a basis for this framework, we reviewed established models used to describe
health behaviour. Structural elements of these models informed the development of an
adherence model for AD that can be used to complement empirical AD treatment trials.
Health behaviour models provide a means to describe factors that affect adherence and
that can mediate the effects of different adherence interventions. Models of adherence
behaviour are important for promoting better treatment outcomes for children with AD
and their families. These models provide a means to identify new targets to improve
adherence and a guide for refining adherence interventions.
Introduction
Atopic dermatitis (AD) is an important and increasing
healthcare problem in children.1–3 AD can cause
discomfort, loss of sleep, fatigue and psychosocial
distress.3 Parents and caregivers can also experience
significant psychosocial distress and fatigue.3 Loss of
productivity in school and at work adds to the burden of
the disease.
There are many effective treatments for AD. Topical
corticosteroids and other immunomodulators are highly
effective in clinical trials.4 Despite this, AD remains
poorly controlled in many patients, resulting in poor
quality of life for both patients and their caregivers.
Failure of topical treatments to achieve success may also
lead to use of potentially toxic systemic treatments.
‘Adherence’, a term that has replaced the more
pejorative ‘compliance’ concept, probably plays a major
role in AD treatment failures.
Poor adherence is common and has a tremendous
effect on health and healthcare expenditures.5–7 Adher-
ence can be poor even when a simple, static treatment
regimen is used.8 In one study of children with AD,
adherence to topical triamcinolone was assessed with
electronic monitors; the mean adherence rate was only
32% over an 8-week period.8 Even patients who have
objectively and subjectively severe atopic skin disease
may not be using their recommended treatment.9
Adherence rates are likely to be even lower over the
extended course of this chronic disease and when
dynamic, multi-agent regimens are prescribed. Poor
adherence has the potential to cause both initial
treatment failure and later loss of treatment effective-
ness (so-called ‘tachyphylaxis’).8 Models of AD treat-
ment that do not account for adherence may be
inadequate for describing the relationship between
treatment and outcomes seen in clinical practice
(Fig. 1).
The purpose of this paper is to review existing models
of health behaviour and to use elements of those models
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to describe a general model that can be used to better
understand, study and manipulate AD adherence
behaviour.
Existing models of health behaviour
Adherence behaviour management plays a substantial
role in treatment regimens of diabetes, hypertension,
chronic heart failure and asthma. Models have been
developed to incorporate the factors affecting adherence
into health recommendations. These models provide a
basis for modelling AD adherence behaviour.
There are three major models used to describe
patients’ health behaviours: the Health Belief Model,
the Health Behaviour Model, and the Social Cognitive
Theory. The Health Belief Model is based on the concept
that people make rational choices about whether to
engage in an advocated behaviour.10–14 In essence,
people are believed to engage in a rational assessment of
the known or presumed costs associated with an
advocated behaviour relative to the anticipated benefits.
The Health Belief Model includes four main concepts
that shape individual assessment and appraisal of
potential costs and benefits: (i) a patient’s perceived
susceptibility to a particular condition; (ii) perceived
severity if the patient were to develop the condition,
including the combined effect of disease, treatment and
sequelae on overall quality of life; (iii) perceived benefits
(a patient’s judgement of how much a recommended
action will reduce their risk of developing the con-
dition or mitigate its negative consequences); and
(iv) perceived barriers (a patient’s judgement of the
aggregate costs of the recommended action, including
financial, psychological and time costs to the patient or
their family). More recent forms of the Health Belief
Model further outline two other factors in the decision
to engage in a behaviour: (i) self-efficacy, which is the
patient’s belief that they are capable of taking the
recommended action; and (ii) cues to action, which are
aids that teach or remind the patient about the
recommended action.10
Although the Health Belief Model identifies internal
processes shaping health behaviours, the Health Behav-
iour Model highlights external factors that either shape
patients’ thinking or exert direct effects on behaviour.
Modifications to the Health Behaviour Model, which led
to the Health Care Delivery Model devised by Andersen
and Aday,15 emphasize the effect of external enabling
factors on patient adherence. These external factors
include both contextual barriers in patients’ and care-
givers’ lives, and characteristics of the healthcare
system. External factors, particularly changes over
which the clinician has control and that are feasible
at the practice level, may be especially good targets for
adherence interventions (Fig. 2).
The Social Cognitive Theory emphasizes the concept
of reciprocal determinism (a ‘continuous, dynamic
interaction between the individual, the environment
and behaviour’).10,14 This is an important consideration
in adherence behaviour because outcomes of treatment
may affect subsequent adherence behaviour (Fig. 3). In
particular, better initial treatment outcomes may
Figure 1 Patient adherence to treatment affects disease outcome.
Atopic dermatitis (AD) treatment studies are often based on a very
simple model: that treatment of the disease improves the outcome.
Such models do not account for the rich variation in human
behaviour that contributes to the outcome of treatment. The effect
of any treatment on a disease outcome is contingent upon
adherence to the recommended treatment. Adherence is a mea-
surable variable, and accounting for adherence improves under-
standing of the relationship between a treatment and its effect on
disease outcome. The development of interventions that improve
adherence may be just as valuable as new pharmacological agents
in improving treatment outcomes in AD. Similarly, a better
understanding of factors that affect adherence is as important to
the development of adherence interventions as an understanding
of immune mechanisms in AD is to the development of new
pharmacological therapies.
Figure 2 Internal and external factors that affect adherence
behaviour. Adherence behaviour is shaped by both internal and
external factors. The external factors may have direct effects on
adherence or may modulate patients’ internal thinking. External
factors are good targets for adherence interventions and include
both contextual barriers in the lives of patients ⁄ caregivers and
characteristics of the healthcare system.
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increase the perceived value of a treatment, resulting in
better adherence.
Integrating existing models to form an
adherence model for AD
Based on the existing models, internal ⁄ psychosocial
factors that are anticipated to modulate patients’
adherence include perceptions about the severity of
disease; the benefits, risks and costs of treatment; trust
in the clinician; and self-efficacy in treatment use
(Fig. 3). External factors that can be manipulated
include reminder systems, access to care, and patient
education (Fig. 3). Modelling predicts that clinicians can
leverage several factors to promote better adherence
including increasing trust in the clinician, providing
specific cues to action and reducing the perceived
burden of treatment. The effect of such interventions
can be tested in clinical trials using objective monitoring
of adherence behaviour.
A critical feature of model-based research is the ability
to test and examine the mechanisms by which inter-
ventions improve outcomes. AD treatment education
programmes can improve adherence, but as yet we do
not know why.16–18 The educational programme could
work simply by reducing patients’ fears, or it may be
effective because it elicits greater trust in the clinician,
more support from family members, incorporation of
cues to action, or a reduction in the apparent burden of
treatment. By knowing specifically how educational
interventions improve AD adherence, newer, less com-
plicated and perhaps even more effective interventions
could be developed.
Written action plans (WAPs), widely used in treating
children with asthma, provide a potential intervention
to improve adherence in children with AD.19 WAPs are
designed to empower patients to respond appropriately
to the waxing and waning course of the disease. WAPs
target factors that are central to adherent behaviour:
cues to action (discrete criteria that patients can use to
easily determine if action is required); self-efficacy over
the health condition; and a sense of treatment efficacy.
Both the content of the WAP and the communication
between patient and provider when the WAP is
developed are intended to convey the message, ‘this
plan can help you control your condition’. Asthma and
AD share a chronic relapsing and remitting course that
requires variation in management over time, making
AD another logical target for a WAP intervention.19
Development and testing of a WAP for AD would focus
on whether the effect of the WAP on adherence is a
function of improved trust, improved self-efficacy,
improved perceived risk–benefit ratio, or some combi-
nation of these effects (Fig. 4).
Follow-up consultations increase patients’ use of
medication, and the use of an early follow-up visit has
also been proposed as a means to improve adherence in
patients with AD.8,20 This intervention is anticipated to
function differently from a WAP. An early follow-up
intervention increases patient and parent willingness to
adhere to treatment over the short term.21 The
improved adherence to treatment that occurs for a
short time before a clinic visit is known as ‘white-coat
compliance’.8,22,23 The feedback of outcome on adher-
ence in the adherence behaviour model (a combination
of factors in the three models outlined above) (Fig. 3)
predicts that an early return visit intervention may
also improve long-term AD treatment outcomes by
Figure 3 Outcomes of treatment may affect adherence behaviour.
There is a reciprocal relationship between treatment outcomes and
adherence behaviour. Better treatment outcomes may positively
affect internal factors that guide patients’ adherence behaviour.
Recognizing this relationship helps identify the potential to use
programmes that improve initial treatment outcomes to help
further promote better adherence.
Figure 4 Modelling the mechanism for the effects of a written
action plan (WAP) on adherence behaviour. A model provides a
basis for determining how an intervention functions. The model of
a WAP intervention predicts several mechanisms by which a WAP
can enhance adherence behaviour. Measuring these factors in a
WAP intervention trial allows identification of how the WAP is
functioning. This may help facilitate refinement of the intervention
to achieve improved adherence.
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increasing patients’ and caregivers’ perceptions of
treatment efficacy and thus increasing their ongoing
level of adherence. Analysis of an early follow-up
intervention would help refine the model of adherence
behaviour, determining not only whether the interven-
tion is effective, but also whether it is acting as expected
on other points within the model.
Conclusion
Scientific models are used to systematically guide
research, to understand the most salient leverage points
for intervention, and to guide study design and evalu-
ation. In studies of the immunology of AD, researchers
develop comprehensive models of cells, adherence
proteins and cytokines to guide hypothesis-based
research. Likewise, in the realm of behavioural research,
a comprehensive conceptual model is needed. Concep-
tual models help guide the design of empirical studies,
the interpretation of resultant findings, the development
of clinical intervention trials, and, ultimately, the
practice of evidence-based medicine and clinical care.
Consider a child with AD who is not improving with
treatment as expected. We know that poor adherence to
treatment is a likely cause, as simply admitting the
patient to the hospital and applying the medication on
an inpatient basis typically results in very rapid clearing
of the disease. There could be many reasons for
nonadherence. The parents may not have the financial
or time resources to purchase or use the medication.
The parents may be fearful of the potential side-effects of
treatment, or they may not trust that the medication
will work. They may not understand how the medica-
tion is supposed to be used. They may simply forget to
apply the medication, or the child might refuse to allow
the medicine to be applied because they do not like how
it feels. A model that organizes and describes the factors
affecting adherence and the resulting effect on outcomes
provides a framework for caring for patients and for
developing and refining targeted interventions.
The outcomes of the most prevalent skin diseases are
inextricably linked with human behaviours. Although
human behaviour is complex, it is perhaps no more
complex than well-studied pathophysiological systems.
A basic understanding of the factors that influence
health behaviours and how healthcare interactions can
be optimized to prevent or manage these diseases is vital
to the advancement of skin disease treatment. Human
behaviour must be assessed with the same scientific
rigour as other disciplines of basic investigational
dermatology. Our nascent collective understanding of
adherence behaviour will benefit from models that
frame the adherence problem. These models will provide
a rational framework for hypothesis-testing research
and for further theoretical development. It is hoped that
these models will form a framework for future research
that will benefit both paediatric patients with AD and
those with other dermatological diseases.
Learning points
• Atopic dermatitis (AD) is an important disease
of childhood that causes psychosocial distress for
both patients and caregivers. Nonadherence to
topical medications probably plays a role in AD
treatment failures.
• Scientific models are used to systematically guide
research and study design, to interpret results and
develop appropriate interventions, and to enhance
the practice of evidence-based medicine.
• Conceptual models are needed for the treatment
of AD. Failure to account for the role of decreased
adherence in AD treatment failures may result in
inadequate models.
• The three major models to describe health
behaviours are: the Health Belief Model, the Health
Behaviour Model and the Social Cognitive Theory.
Existing models can be used to develop an adher-
ence model for AD.
• Modelling predicts that clinicians can leverage
several factors to improve adherence, e.g. increas-
ing trust in clinicians, providing specific treatment
cues and decreasing the burden of treatment. The
effect of these interventions can be tested in studies
using objective adherence monitoring.
• Understanding the mechanism by which pro-
posed interventions improve adherence is essential
to refining models of treatment adherence.
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